Physician profile
Holly E Kanavy
NPI 1386965408
$43,306.60
in general payments reported to CMS, 2019-2025
27 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,661 · 2020: $7,222 · 2021: $8,498 · 2022: $6,628 · 2023: $3,761 · 2024: $6,659 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,200 · Food and Beverage: $3,701 · Education: $345 · Travel and Lodging: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,200.00 |
| Food and Beverage | $3,700.76 |
| Education | $345.05 |
| Travel and Lodging | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17,595.41 | 2019-2025 | Cosentyx |
| Dermavant Sciences, INC. | $6,784.48 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $5,917.53 | 2020-2024 | Sotyktu |
| Janssen Biotech, INC. | $4,465.99 | 2019-2025 | Tremfya |
| Abbvie INC. | $2,442.80 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $1,455.00 | 2019 | |
| Ucb, INC. | $1,338.34 | 2020-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $1,326.34 | 2020-2025 | Dupixent |
| Genzyme Corporation | $595.64 | 2020-2025 | |
| Lilly USA, LLC | $247.49 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $227.96 | 2019-2025 | Cabtreo |
| Pfizer INC. | $209.43 | 2024-2025 | |
| Amgen INC. | $186.12 | 2020-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $120.54 | 2019-2022 | |
| Incyte Corporation | $113.13 | 2024-2025 | Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $84.48 | 2024 | Zoryve |
| Botanix Sb INC | $65.67 | 2025 | Sofdra |
| Regeneron Pharmaceuticals, INC. | $49.73 | 2024-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $22.34 | 2020 | |
| Galderma Laboratories, L.P. | $21.26 | 2024 | |
| Epi Health, LLC | $20.00 | 2022 | |
| Leo Pharma INC. | $16.92 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Kanavy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.